Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Polyphor
Polyphor
Activities:
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development
Kalina Scott appointed new CFO of Polyphor
Research & Development
New hope against antibiotic resistance: Outer-Membrane Protein Targeting Antibiotics
OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens
Recruitment
Debra Barker appointed as new CMDO of Polyphor
Polyphor has announced the appointment of Dr Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO)
Research & Development
Polyphor appoints Michael Altorfer as Chief Executive
He replaces Jean-Pierre Obrecht, who will continue as a member of the Board of Directors
Research & Development
Roche signs licensing agreement with Polyphor to combat multi-drug resistant infections
Makes an upfront payment of CHF35m to Polyphor in deal that could be worth up to CHF500m
Research & Development
Polyphor signs MacroFinder collaboration with Boehringer Ingelheim
Will use technology to identify drug candidates addressing therapeutic targets chosen by BI
Subscribe now